-+ 0.00%
-+ 0.00%
-+ 0.00%

Is Ionis Pharmaceuticals (IONS) Undervalued After TRYNGOLZA EU Approval And Diranersen Data?

Simply Wall St·11/18/2026 15:15:12
Listen to the news

Ionis Pharmaceuticals (IONS) is back in focus after a busy November, with European approval for TRYNGOLZA in severe hypertriglyceridemia and fresh Phase 2 data for Alzheimer’s candidate diranersen drawing investors toward the stock.

Even with November’s flurry of updates, investor sentiment around Ionis Pharmaceuticals has been weak. The share price is $26.96, with a 30-day share price return that declined 37.21%, contributing to a year-to-date share price drop of 66.16% and a 1-year total shareholder return that fell 63.81%.

Scan how Ionis Pharmaceuticals compares to other late-stage biotech opportunities by reviewing a hand-picked 18 high quality undiscovered gems that are also pushing new treatments toward commercial scale.

Ionis Pharmaceuticals now trades near multi year lows despite fresh data and a new EU approval that both expand its potential. Has most of the rerating already happened, or is the valuation still pricing in too little?

Most Popular Narrative: 61% Undervalued

On the analyst consensus Narrative on Simply Wall St, Ionis Pharmaceuticals screens as materially undervalued, with a fair value of $69.30 against a last close of $26.96. This puts a lot of weight on how its late stage assets translate into real earnings over time.

The main requirement for Ionis Pharmaceuticals is successful execution on the APOC3 and neurology franchises, including broad TRYNGOLZA adoption, progression of ION-775, and effective commercialization of ZANVASTRO alongside other CNS programs. The current numbers and external analyst views imply the share price reflects limited credit for Ionis Pharmaceuticals’ commercial APOC3 opportunity and royalty streams, which keeps the valuation aligned with a bullish setup.

See why 20 investors see Ionis Pharmaceuticals as 61% undervalued.

Result: Fair Value of $69.30 (UNDERVALUED)

Still, the reset to TRYNGOLZA sales guidance and the loss of pelacarsen related royalty expectations both sit squarely against the bullish Ionis Pharmaceuticals narrative.

Find out about the key risks to this Ionis Pharmaceuticals narrative.

Another View: Ionis Pharmaceuticals On Sales-Based Valuation

There is a very different picture when Ionis Pharmaceuticals is judged on its P/S ratio instead of a discounted cash flow model. The stock trades on 4.7x sales, while a fair ratio of 3.9x suggests the market could move toward a lower multiple over time.

The same metric across the US Biotechs industry sits near 9.9x, and peer companies average about 10.9x. That combination of a discount to sector and peers, yet a premium to the fair ratio, points to a mix of opportunity and valuation risk. The question for investors is which way that gap closes first.

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:IONS P/S Ratio as at Nov 2026
NasdaqGS:IONS P/S Ratio as at Nov 2026

Next Steps

Sentiment around Ionis Pharmaceuticals is clearly mixed, with valuation signals and clinical news pulling in different directions. If you want to move fast and shape your own view based on the positives, start by weighing the 2 key rewards.

Ready For More Ideas Beyond Ionis Pharmaceuticals?

If Ionis Pharmaceuticals has you rethinking where risk and potential really sit, broaden your watchlist and pressure test your thesis against other opportunities.